A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT07218341 · tracked via the Priya Life Science China tracker

Sponsor

Eli Lilly and Company

Phase

Phase 4

Started

2026-03-09

Last updated

2026-09-04

Condition(s) studied

Chronic Lymphocytic LeukemiaLymphoma, Small Lymphocytic

Investigational drug(s) / intervention(s)

PirtobrutinibIdelalisib

Pirtobrutinib: Administered orally

Idelalisib: Administered orally

Study summary

This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Are actively participating in study J2N-MC-JZNN/LOXO-BTK-20020 Exclusion Criteria: * This is not applicable to this study

Primary outcome measure(s)

Percentage of Participants with a Grade 3 or Higher Treatment-emergent Adverse Events (AEs) — Time from First Dose of Study Intervention (Study Day 1) through 30 Days After Last Dose of Study Intervention or Start of New Anticancer Therapy, whichever is Earlier

Trial sites (50)

Facility	City	Region	Status
Mitchell Cancer Institute	Mobile	Alabama	Recruiting
Arizona Oncology Associates, P.C. - HOPE	Tucson	Arizona	Not Yet Recruiting
Cancer Specialists, LLC	Jacksonville	Florida	Recruiting
Minnesota Oncology Hematology, P.A.	Coon Rapids	Minnesota	Recruiting
Cayuga Cancer Center	Ithaca	New York	Not Yet Recruiting
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York	New York	New York	Recruiting
Oncology Hematology Care Inc	Cincinnati	Ohio	Not Yet Recruiting
Texas Oncology - Paris	Fort Worth	Texas	Not Yet Recruiting
US Oncology - Texas Oncology	Kyle	Texas	Not Yet Recruiting
The Alfred Hospital	Melbourne	Australia	Not Yet Recruiting
LKH - Universitätsklinikum der PMU Salzburg	Salzburg	Austria	Not Yet Recruiting
AZ Delta	Roeselare	Belgium	Not Yet Recruiting
Princess Margaret Cancer Centre - University Health Network	Toronto	Canada	Not Yet Recruiting
Xuanwu Hospital Capital Medical University	Beijing	China	Not Yet Recruiting
Hunan Cancer Hospital	Changsha	China	Not Yet Recruiting
Sun Yat-sen University Cancer Center	Guangdong	China	Not Yet Recruiting
Nanfang Hospital of Southern Medical University	Guangzhou	China	Not Yet Recruiting
Gansu Provincial Cancer Hospital	Lanzhou	China	Not Yet Recruiting
The First Affiliated Hospital of Nanchang University	Nanchang	China	Not Yet Recruiting
Fudan University Shanghai Cancer Center	Shanghai	China	Not Yet Recruiting
Taizhou Hospital of Zhejiang Province	Taizhou	China	Not Yet Recruiting
Hematology Hospital of the Chinese Academy of Medical Sciences	Tianjin	China	Recruiting
Tianjin Medical University Cancer Institute & Hospital	Tianjin	China	Not Yet Recruiting
Affiliated Cancer Hospital of Xinjiang Medical University	Ürümqi	China	Not Yet Recruiting
The Affiliated Hospital of Xuzhou Medical College	Xuzhou	China	Not Yet Recruiting
Henan Cancer Hospital	Zhengzhou	China	Not Yet Recruiting
University Hospital Center Zagreb	Zagreb	Croatia	Not Yet Recruiting
Fakultni nemocnice Hradec Kralove	Hradec Králové	Czechia	Not Yet Recruiting
Centre Henri Becquerel	Rouen	France	Not Yet Recruiting
Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet	Budapest	Hungary	Not Yet Recruiting
Debreceni Egyetem	Debrecen	Hungary	Not Yet Recruiting
St. James's Hospital	Dublin	Ireland	Not Yet Recruiting
Beaumont Hospital	Dublin	Ireland	Not Yet Recruiting
Tel Aviv Sourasky Medical Center	Tel Aviv	Israel	Not Yet Recruiting
Azienda Ospedaliero - Universitaria Nazionale Santi Antonio e Biagio e Cesare Arrigo	Alessandria	Italy	Not Yet Recruiting
Azienda Ospedaliera Universitaria Careggi	Florence	Italy	Not Yet Recruiting
Presidio Ospedaliero Papardo	Messina	Italy	Not Yet Recruiting
Fondazione IRCCS San Gerardo dei Tintori	Monza	Italy	Not Yet Recruiting
Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia	Perugia	Italy	Not Yet Recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Rome	Italy	Not Yet Recruiting

+ 10 more sites — see the full list on the official registry below.

More Eli Lilly and Company trials in China

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) Recruiting

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations Active, not recruiting

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight Recruiting

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) Recruiting

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight Recruiting

Other trials for the same condition

A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies Active, not recruiting

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) Recruiting

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) Recruiting

A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL Recruiting

A Long-term Extension Study of PCI-32765 (Ibrutinib) Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07218341 on ClinicalTrials.gov ↗ ← All trials in China